COMMUNIQUÉS West-GlobeNewswire

Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
12/02/2019
SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in- [...]
Canntab Enters into Supply Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal
12/02/2019
Canntab enters into 3-way supply agreement to purchase up to 1,000 kg of 2018 hemp crop TORONTO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab”), a leader in the [...]
Parkinson’s Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development
12/02/2019
Competitive Differentiation of ProMIS Antibodies is Key to Ongoing Partnering Discussions with Large Pharmaceutical Companies TORONTO and CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. ( [...]
Canada House Wellness Group Inc. Announces Full Operations in its Facility, Commences Full-Scale Production of EU-GMP Certified Cannabis
12/02/2019
Canada House is Positioned to Leverage its Newly Awarded Sales License and Will Have EU-GMP Certified Medical Grade Cannabis Ready for Patients by July 2019 TORONTO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Canada House [...]
Microbix Reports Results for Q1 Fiscal 2019
12/02/2019
Lower Sales, Improving Gross Margin, Positive Cash Flow from Operations TORONTO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix ® ), an innovator of biological products and technologies, [...]
Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program
12/02/2019
SEOUL, South Korea and SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture formed in September [...]
Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting
12/02/2019
Results from Two Pivotal Phase 3 Clinical Trials of Lead Candidate VP-102 in the Treatment of Molluscum Contagiosum to be Presented on March 2, 2019 WEST CHESTER, Pa., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Verrica [...]
Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019
12/02/2019
CRANBURY, N.J., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 28, 2019 at 8:30 a.m. ET to [...]
Tetra Bio-Pharma Provides Update on its Neuropathic and Chronic Pain Drug Development Program
12/02/2019
ORLEANS, Ontario, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (" Tetra " or the " Corporation ") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, [...]
BriaCell Appoints Jamieson Bondarenko to its Board of Directors
12/02/2019
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 12, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) (" BriaCell " or the " Company "), an immuno-oncology focused biotechnology [...]
Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
12/02/2019
GAITHERSBURG, Md., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan [...]
MediPharm Labs Signs $35 Million Private Label Cannabis Oil Sale Agreement with Option for Additional $13.5 Million
12/02/2019
TORONTO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (“MediPharm”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce [...]
CorVel Announces Expansion of Stock Repurchase Program
12/02/2019
IRVINE, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), reported that the Company’s Board of Directors has approved a 1,000,000 share expansion to its existing stock repurchase program, [...]
Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018
12/02/2019
Total Revenues for Fiscal 2018 were $114.5 Million, up 11% Over Fiscal 2017; In-line with Recently Provided 2018 Expected Revenues of $113 Million and $115 Million Full-Year Proprietary Products Revenues up 14% Year- [...]
RAMSAY GENERALE DE SANTE : augmentation de capital avec maintien du droit préférentiel de souscription
12/02/2019
COMMUNIQUE DE PRESSE Ramsay Générale de Santé confirme son intention de lancer une augmentation de capital avec maintien du droit préférentiel de souscription Paris, 12 février 2019 - Ramsay Générale de Santé S.A. (« [...]
Transactions in relation to share buyback program
12/02/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium
12/02/2019
LONDON, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of preliminary results from the Phase II CALYPSO study of the savolitinib / [...]
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
12/02/2019
- Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe - Dermira to receive an option fee of $30 million - Lebrikizumab is an investigational anti-IL-13 [...]
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) Split Dosing Regimen
12/02/2019
Media Release Copenhagen, Denmark, February 12, 2019 DARZALEX split dosing regimen approved by U.S. FDA Provides healthcare professionals with option to split first DARZALEX infusion over two consecutive days Approval [...]

Pages